Novus Therapeutics (NVUS) Stock Price, News & Analysis

Company Overview

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Key Stats

• Today's Range: $3.00 to $3.11
• 50-Day Range: $9.85 to $16.50
• 52-Week Range: $4.50 to $27.32
• Volume: 175,430 shs
• Average Volume: 78,851 shs
• Market Capitalization: $4.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NVUS Stock Analysis - Frequently Asked Questions

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics, Inc. (NASDAQ:NVUS) released its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) earnings per share for the quarter, missing the consensus estimate of ($1.64) by $3.87.

When did Novus Therapeutics' stock split?

Shares of Novus Therapeutics reverse split on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Novus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novus Therapeutics investors own include SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Miragen Therapeutics (MGEN), Selecta Biosciences (SELB) and Tonix Pharmaceuticals (TNXP).

Company Calendar

• Last Earnings: 11/16/2020
• Today: 5/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NVUS
• CIK: 1404281
• Web: novustherapeutics.com
• Phone: 949-238-8090
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($21.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,010,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -133.49%
• Return on Assets: -30.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.78
• Quick Ratio: 18.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.13 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 1,436,000
• Free Float: N/A
• Market Cap: $4.38 million
• Optionable: Not Optionable
• Beta: 2.07